Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
Relmada Therapeutics (Nasdaq: RLMD) said it will report third quarter 2025 financial results and recent business progress on Thursday, November 13, 2025 at 4:30 PM ET via a conference call and webcast.
Participant dial-in numbers are US: 1-877-407-0792 and International: 1-201-689-8263. A webcast replay will be available in the Investors section at https://www.relmada.com/investors/ir-calendar.
Relmada Therapeutics (Nasdaq: RLMD) ha dichiarato che comunicherà i risultati finanziari del terzo trimestre 2025 e i progressi aziendali recenti durante una conferenza telefonica e webcast giovedì 13 novembre 2025 alle 16:30 ET.
Numeri di accesso per i partecipanti: USA: 1-877-407-0792 e Internazionale: 1-201-689-8263. Una replay del webcast sarà disponibile nella sezione Investitori all'indirizzo https://www.relmada.com/investors/ir-calendar.
Relmada Therapeutics (Nasdaq: RLMD) dijo que informará los resultados del tercer trimestre de 2025 y el progreso comercial reciente durante una conferencia telefónica y webcast el jueves 13 de noviembre de 2025 a las 4:30 PM ET.
Los números de marcación para los participantes son EE. UU.: 1-877-407-0792 y Internacional: 1-201-689-8263. Una repetición del webcast estará disponible en la sección de Inversores en https://www.relmada.com/investors/ir-calendar.
Relmada Therapeutics (나스닥: RLMD) 은 2025년 3분기 재무 실적 및 최근 사업 진행 상황을 2025년 11월 13일 목요일 동부 표준시 4:30 PM에 컨퍼런스 콜과 웹캐스트를 통해 발표할 것이라고 말했습니다.
참여자 전화 접속 번호는 미국: 1-877-407-0792와 국제: 1-201-689-8263 입니다. 웹캐스트 재생은 https://www.relmada.com/investors/ir-calendar의 투자자 섹션에서 이용 가능합니다.
Relmada Therapeutics (Nasdaq : RLMD) a déclaré qu'il divulguerait les résultats financiers du T3 2025 et les progrès récents de l'activité lors d'une conférence téléphonique et d'un webcast le jeudi 13 novembre 2025 à 16h30 ET.
Les numéros d'appel des participants sont États-Unis : 1-877-407-0792 et International : 1-201-689-8263. Une rediffusion du webcast sera disponible dans la section Investisseurs à l'adresse https://www.relmada.com/investors/ir-calendar.
Relmada Therapeutics (Nasdaq: RLMD) gab bekannt, dass die Ergebnisse des dritten Quartals 2025 und die jüngsten Geschäftsentwicklungen am Donnerstag, 13. November 2025 um 16:30 Uhr ET per Telefonkonferenz und Webcast bekannt gegeben werden.
Teilnehmer-Telefonnummern sind USA: 1-877-407-0792 und International: 1-201-689-8263. Eine Webcast-Wiederholung ist im Bereich Investoren unter https://www.relmada.com/investors/ir-calendar verfügbar.
Relmada Therapeutics (ناسداك: RLMD) ذكرت أنها ستعلن عن نتائج الربع الثالث من عام 2025 والتقدم التجاري الأخير عبر مكالمة مؤتمر وبث مباشر يوم الخميس 13 نوفمبر 2025 الساعة 4:30 مساءً بتوقيت الشرقية عبر الهاتف وبث مباشر.
أرقام الدخول للمشاركين هي الولايات المتحدة: 1-877-407-0792 و الدولية: 1-201-689-8263. سيكون هناك إعادة لعرض البث عبر الويب في قسم المستثمرين على العنوان https://www.relmada.com/investors/ir-calendar.
- None.
- None.
CORAL GABLES, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced plans to host a conference call and webcast on Thursday, November 13, 2025 at 4:30 PM ET to discuss financial results for the third quarter ended September 30, 2025 and recent business progress.
Conference Call and Webcast Information:
- Date: Thursday, November 13, 2025 at 4:30 PM ET
- Participant Dial-in (US): 1-877-407-0792
- Participant Dial-in (International): 1-201-689-8263
- Webcast Access: Click Here
A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.
For more information, visit www.relmada.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
Media Inquiries:
Corporate Communications
media@relmada.com
FAQ
When will Relmada Therapeutics (RLMD) release its Q3 2025 financial results?
How can investors join the Relmada (RLMD) Q3 2025 conference call and webcast?
Where will the Relmada (RLMD) webcast replay for the November 13, 2025 call be posted?
What topics will Relmada (RLMD) cover during the November 13, 2025 call?
What time should shareholders dial in for Relmada's (RLMD) Q3 2025 call in Eastern Time?
Will international participants be able to access Relmada (RLMD) Q3 2025 call?
